Home » Newsletters » BioWorld Science

BioWorld Science

June 13, 2012

View Archived Issues

SIRT1 activation investigated in models of obesity

Novel data reported on GKM-001 in diabetes and obesity

Phase I results encourage continued clinical evaluation of PEGylated C-peptide

First-in-human data disclosed on gene-modified T cells to facilitate stem cell transplants

Roche presents novel LRRK2 inhibitors

Bristol-Myers Squibb patents novel inhibitors of CYP17

Novel diagnostics disclosed by Janssen Pharmaceuticals

Merck & Co. reports new CGRP receptor antagonists

New PI3K inhibitors developed in U.S.

Synta Pharmaceuticals prepares new IL-2/CRAC-targeted products

Pharmanest launches phase II study of SHACT

Eltoprazine study in Parkinson's disease meets primary objective

Summit achieves milestone in development of SMT-C1100

Novel dipeptidyl peptidase IV inhibitor shows promise in diabetes/obesity models

Combination therapy shows surprising synergistic efficacy in Batten disease model

VaxInnate begins phase I H5N1 vaccine study

ImaginAb and BZL Biologics expand collaboration

Invega Sustenna formulation enters phase III trials

Greer reports data from phase III sublingual immunotherapy trial

Proof-of-concept study begins for Ampyra

Cempra starts phase II trial in gonococcal infections

Lead Tokai product receives FDA fast track status

Two first-in-class PolyMedix products receive approved generic names

Jazz Pharmaceuticals completes acquisition

FDA grants fast track status to synthetic ectodysplasin-A

Enrollment under way in NX-1207 trial in low-grade localized prostate cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 13, 2025
Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal
BioWorld
The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...
Proteomics study explores how protein changes influence disease
BioWorld Science
Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...
Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance
BioWorld
Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.